Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Viridian Therapeutics ( (VRDN) ) is now available.
On March 30, 2026, Viridian Therapeutics reported positive topline results from its phase 3 REVEAL-1 trial of elegrobart in patients with active thyroid eye disease, positioning the drug as a potential first subcutaneous autoinjector therapy for the condition. The 132-patient study showed highly statistically significant improvements in proptosis responder rates versus placebo for both every-four-week and every-eight-week dosing, clinically meaningful gains in diplopia outcomes, and a generally well-tolerated safety profile with low, tinnitus-only hearing events.
The data underscore a meaningful competitive challenge to the only currently marketed intravenous TED therapy, which generated about $2 billion in 2025 despite limited penetration, highlighting potential for market expansion via a more convenient at-home, self-administered option if approved. Viridian said the companion REVEAL-2 phase 3 study in chronic TED remains on track for a topline readout in the second quarter of 2026, and the company is preparing for a potential biologics license application submission for elegrobart in the first quarter of 2027 as it targets future commercial revenues alongside veligrotug.
The most recent analyst rating on (VRDN) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
The score is primarily constrained by weak financial performance driven by deep losses and persistent negative free cash flow, despite a strong no-debt balance sheet and improved 2025 revenue. Technical indicators add a modest negative bias due to weaker near-term momentum, while valuation is difficult to justify positively given the negative P/E and lack of dividend data.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics, Inc., based in Waltham, Mass., is a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases. The company is advancing candidates including elegrobart, a subcutaneous IGF-1R monoclonal antibody for thyroid eye disease, and veligrotug, and ended Q4 2025 with $875 million in cash to support its plans through profitability.
Average Trading Volume: 1,429,974
Technical Sentiment Signal: Buy
Current Market Cap: $2.8B
For an in-depth examination of VRDN stock, go to TipRanks’ Overview page.